Xencor Inc at Barclays Global Healthcare Conference Transcript
Good afternoon. Welcome to Barclays Healthcare Global Conference. And of course, you can e-mail me and my associates if you have questions. But -- my name is Peter Wilson. I'm one of the biotech analysts at Barclays covering mid-cap oncology, and really delighted to have with us the CEO from Xencor, Bassil Dahiyat.
Questions & Answers
And I guess the first thing really for me is always like fantastic breadth of development over the years, like the way you kind of view your technology in that antibody space and kind of how it differentiates. I know now it has kind of changed to a certain degree because you're thinking bispecifics, et cetera.
But just kind of what's the differentiation within that core that pharma companies want to partner with you?
So the issue of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |